"Critical Path" Priorities List Likely To Include Clinical Trial Design, FDAer Says

FDA expects to release its Critical Path opportunities list by the end of the summer. Issues concerning clinical trial design and biomarkers appeared "orders of magnitude" more often than other topics in stakeholder comments, FDA Regulatory Counsel Rovin says at BIO annual meeting.